The Patient-Centric Approach in Health Economics

By Staff Writer

January 24, 2024

A Paradigm Shift in Health Economics and Outcomes Research

HEOR, which refers to health economics and outcomes research, is a realm that is difficult to navigate due to its complexity, diverse nature, and numerous facets. Nevertheless, there is one key element that stands out: the patient is the most important element. With the purpose of shedding light on the influence that this trend has on healthcare systems around the world, this article investigates the increased emphasis on a patient-centric approach in HEOR.

The Core of Health and Education

At its core, HEOR is a multidisciplinary field that aims to enhance the accessibility, fairness, and efficiency of healthcare systems for patients. It requires an understanding and appreciation of factors that significantly affect patients’ health and their experiences. This field prioritises what truly matters to patients.

The Importance of ISPOR in the Support of Patient-Centred Patient Care

Rob Abbott, as the CEO and Executive Director of The International Society for Pharmacoeconomics and Outcomes Research (ISPOR), emphasised the importance of encouraging patient-focused work. He defined this as a collaborative and meaningful interaction between patients and researchers, occurring throughout the entire research process. During the decision-making process, patient experiences, values, and expertise serve as guiding principles. This helps to ensure that the data collected ultimately contributes to the improvement of patient outcomes.

Progress and Obstacles

Significant progress has been made in centering patients in HEOR, but much work remains. We need to boost the patient’s voice and create a more patient-focused decision-making process. However, integrating the patient throughout the entire healthcare journey presents significant challenges. 

Regarding the Future Strategy of ISPOR and the Function of HEOR

As ISPOR moves on with a new plan for the year 2024, it is making concerted efforts to establish HEOR as a crucial instrument for addressing the most significant challenges in the field of global healthcare. Affordability, the impact of the rapid digitalisation of health care, and the increased desire in providing comprehensive health care are some of these factors. The patient, on the other hand, is the focal point of each and every one of these issues.

Concluding remarks

When it comes to HEOR, the patient-centric approach focuses not only on improving people’s health but also on improving the patient experience in situations where their health has been compromised. In this context, it refers to making sure that the patients’ voices are heard and that their requirements are addressed.

Reference url

Recent Posts

pharmaceutical pricing issues
      

Pharmaceutical Pricing Issues: Beyond Overpricing and Profit Motives

💊 Are high drug prices justified by R&D investments, or is there more to the story?

In a thought-provoking critique, a recent BMJ article argues that profit motives are driving pharmaceutical pricing issues while highlighting the tough decisions regarding access to Alzheimer’s drugs in the UK. It raises vital concerns about the implications for lower-income countries and emphasizes the need for a balanced discussion on drug pricing and innovation.

Curious about the complexities of pharmaceutical pricing and how they shape global health access? Dive into the full article for a nuanced exploration!

#SyenzaNews #pharmaceuticals #HealthEconomics #healthcarepolicy

Zimislecel type 1 diabetes
   

Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential

🚀 What if we could revolutionize Type 1 diabetes treatment?

Vertex Pharmaceuticals has made significant strides with its promising phase 1/2 trial results for **zimislecel**, a stem cell-derived therapy that not only restores insulin production but also drastically reduces severe hypoglycemic events. As phase 3 trials commence, this breakthrough could reshape care for T1D patients and potentially reduce long-term healthcare costs.

Curious to learn how zimislecel and other potential cell therapies may redefine diabetes management? Click to read more!

#SyenzaNews #biotechnology #HealthEconomics

biosimilar clinical approach
    

Biosimilar Clinical Approach

🚀 How is the EMA’s new biosimilar clinical approach changing the landscape of drug approvals in Europe?

With a focus on tailored clinical assessments, the EMA is streamlining the pathway for biosimilars by allowing analytical data to take precedence over large-scale comparative efficacy studies. This shift promises to enhance patient access to life-saving therapies while maintaining rigorous safety standards.

Dive deeper into the implications of this innovative regulatory approach and find out how it can impact health economics and market access.

👉 Read more in the full article!
#SyenzaNews #regulatoryaffairs #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.